The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10439 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine

Open Access | Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects

September 7, 2010 - 14:22 -- Kabogo Ndegwa
Author(s): 
Abdulla S, Amuri B, Kabanywanyi AM, Ubben D, Reynolds C, Pascoe S, Fitoussi S, Yeh C, Nuortti M, Sechaud R, Kaiser G, Lefevre G
Reference: 
Malaria Journal 2010, 9:253 (3 September 2010)

Considering that cherry was the preferred flavour, and that the novel A-L dispersible tablet demonstrated similar pharmacokinetic performances to the tablet administered crushed, a cherry-flavoured A-L dispersible tablet formulation was selected for further development and testing in a large efficacy and safety study in African children with malaria.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

Evaluation of Recurrent Parasitemia after Artemether-Lumefantrine Treatment for Uncomplicated Malaria in Children in Western Kenya

September 2, 2010 - 13:16 -- Patrick Sampao
Author(s): 
Joseph V. Woodring, Bernhards Ogutu, David Schnabel, John N. Waitumbi, Cara H. Olsen, Douglas S. Walsh, D. Gray Heppner, Jr.,and Mark E. Polhemus
Reference: 
Am. J. Trop. Med. Hyg., 83(3), 2010, pp. 458-464

Although recrudescence in some cannot be ruled out, our cohort had a shorter median time to RP compared with other artemether-lumefantrine treatment studies.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia

September 2, 2010 - 12:01 -- Kabogo Ndegwa
Tags: 
Author(s): 
Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E, Gomes M, Ribeiro I, Walter V, Virtanen M, Schlienger R, Cousin M, Chipimo M, Sullivan FM
Reference: 
Malaria Journal 2010, 9:249 (1 September 2010)

These data suggest that exposure to AL in pregnancy, including first trimester, is not associated with particular safety risks in terms of perinatal mortality, malformations, or developmental impairment. However, more data are required on AL use during the first trimester.

Medical Treatment: 

Open Access | Prescribing practice for malaria following introduction of artemether-lumefantrine in an urban area with declining endemicity in West Africa

June 25, 2010 - 09:21 -- Kabogo Ndegwa
Author(s): 
Okebe JU, Walther B, Bojang K, Drammeh S, Schellenberg D, Conway DJ, Walther M
Reference: 
Malaria Journal 2010, 9:180 (24 June 2010)

The study provides evidence for considerable overtreatment for malaria in a West African setting comparable to reports from areas with similar low malaria transmission in East Africa. The data suggest that laboratory facilities may be under-used, and that adherence to negative PHF slide results could significantly reduce the degree of overtreatment.

Person: 
Region: 
City: 
Medical Condition: 
Medical Treatment: 

Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial

April 26, 2010 - 13:43 -- Patrick Sampao
Author(s): 
Antoinette K T., Oumar G., et al.
Reference: 
The Lancet, Volume 375, Issue 9724, 24 April 2010-30 April 2010, Pages 1457-1467

There is a need for new artemisinin-based combination therapies that are convenient, effective, and safe. We compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncomplicated P falciparum malaria.

Medical Condition: 

Open Access | Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania

February 16, 2010 - 14:02 -- Ingeborg van Schayk
Author(s): 
Abdunoor M Kabanywanyi, Christian Lengeler, Prudensiana Kasim, Said King'eng'ena, Raymond Schlienger, Nathan Mulure, Blaise Genton
Reference: 
Malaria Journal 2010, 9:48 (11 February 2010)

Adherence to the dosing regimen and timing of AL administration was very good.

Country: 
Region: 
Medical Condition: 
Medical Treatment: 

Open Access | Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?

January 29, 2010 - 14:33 -- Ingeborg van Schayk
Author(s): 
Bernhards Ogutu, Alfred B Tiono, Michael Makanga, Zulfiqarali Premji, Adama Dodji Gbadoe, David Ubben, Anne Claire Marrast, Oumar Gaye
Reference: 
Malaria Journal 2010, 9:30 (22 January 2010)

This hypothesis highlights an important aspect of the application of effective treatment for malaria control: the need of a shift from passive to active case detection, with treatment of asymptomatic cases being critical in the elimination of parasite reservoirs.

Medical Condition: 

Open Access | Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

December 8, 2009 - 11:55 -- Ingeborg van Schayk
Author(s): 
Shereen Katrak, Anne Gasasira, Emmanuel Arinaitwe, Abel Kakuru, Humphrey Wanzira, Victor Bigira, Taylor G Sandison, Jaco Homsy, Jordan W Tappero, Moses R Kamya, Grant Dorsey
Reference: 
Malaria Journal 2009, 8:272 (30 November 2009)

Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young HIV-infected and uninfected children.

Person: 
Medical Condition: 

Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial

December 7, 2009 - 13:33 -- Ingeborg van Schayk
Author(s): 
Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, et al.
Reference: 
PLoS ONE 4(11): e7871

Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children.

Person: 
Medical Condition: 

Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria

November 13, 2009 - 13:09 -- Ingeborg van Schayk
Tags: 
Author(s): 
Stephan Ehrhardt, Christian G Meyer
Reference: 
Therapeutics and Clinical Risk Management, October 2009

In order to ensure the most achievable and reliable adherence and compliance of children in the treatment of malaria, a dispersible formulation of AL is now attainable. Recent reports on the emergence of resistance to ACT regimens in Asia, however, are alarming.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - artemether-lumefantrine